News & Events

  • March 31, 2017

    Douglas S. Ellenoff, a member of the Firm, wrote an article for LexisNexis; Lexis Practice Advisor titled "Market Trends: Crowdfunding."  

    Click here to read the article

  • March 30, 2017

    Kayne Anderson Acquisition Corp. announced the closing of its initial public offering in the amount of $350,000,000. EG&S acted as counsel to Kayne Anderson.

  • March 24, 2017

    Delaware Court of Chancery granting summary judgment to EG&S client, Shu Kaneko, freeing him from liability on all the claims brought against him by the receiver for Southern China Livestock International, Inc. (SCLI). The Receiver brought claims against Mr. Kaneko seeking approximately $8M in damages, despite SCLI having given Mr. Kaneko a full release as part of a settlement agreement in February 2013, sixteen months before the Receiver first filed suit.  EG&S acted as counel to Mr. Kaneko.  J.B. Horgan, an Associate of the Firm, was on this case from the beginning, having written the summary judgment brief and argued it before the Chancery Court.

  • March 22, 2017

    Northwest Biotherapeutics Inc. announced the closing of their Registered Direct offering in the amount of $7,399,359.  EG&S acted as counsel to the Placement Agent.

  • March 21, 2017

    Rennova Health, Inc. announced the closing of their PIPE offering in the amount of $8,750,000.  EG&S acted as counsel to the Investor.

  • March 17, 2017

    Dragonwave, Inc. announced the closing of their Registered Direct offerings in the amounts of $1,338,340 and $459,658.  EG&S acted as counsel to the Placement Agent.

  • March 16, 2017

    Amanda M. Fugazy, a member of the Firm, will be speaking at NGO's symposium "Fraud & Corruption: Mitigating a Top NGO Risk". Her topic is "Hiring & Vetting: How Well Are You Checking?.  View her presentation here.

    Click here for more info

  • March 15, 2017

    Matlin & Partners Acquisition Co. announced the closing of their initial public offering in the amount of $325,000,000.  EG&S acted as counsel to Matlin.

  • March 10, 2017

    EG&S LLP 2016 Year End Summary

    2016 was another year of significant events and milestones for Ellenoff Grossman & Schole LLP.   We continued to grow our areas of practice, strengthening our existing lines of business and have the privilege of participating in ever increasing matters of complexity. 

    Click here to read more

  • March 09, 2017

    Kayne Anderson Capital Advisors LP announced their plans for an initial public offering that would raise $350 million for a special purpose acquisition company, or “blank-check company,” with its sights on acquiring an energy business.  EG&S is counsel to Kayne.

  • March 02, 2017

    James K. Landau, a member of the Firm, was invited by PLI to participate on a panel discussing the use of social media by attorneys on March 17, 2017.

    Click here for more details

  • February 27, 2017

    Daseke, Inc. and Hennessy Capital Acquisition Corp. II announced the completion of their business combination.  EG&S acted as special SPAC counsel to Hennessy.

  • February 24, 2017

    Arch Therapeutics Inc. announced the closing of their Registered Direct offering in the amount of $6,100,000.  EG&S acted as counsel to the lead Investor.

  • February 23, 2017

    Biopharmaceuticals Ltd. announced the closing of their Registered Direct offering in the amount of $2,500,000.  EG&S acted as counsel to the Placement Agent.

  • February 21, 2017

    Ellenoff Grossman & Schole LLP is proud to announce the addition of a new practice group – Immigration.  John Assadi joins EG&S as a Member and Mauricio Martinez as an Associate.

    Click here to view the announcement

  • February 15, 2017

    Biostage, Inc. announced the closing of their Registered Direct offering in the amount of $8,000,000.  EG&S acted as counsel to the Placement Agent.

  • February 14, 2017

    Moleculin Biotech, Inc. announced the closing of their Underwritten offering in the amount of $4,657,905.  EG&S acted as counsel to the Underwriter.

  • February 10, 2017

    Real Goods Solar, Inc. announced the closing of their Registered Direct offering in the amount of $6,000,000.  EG&S acted as counsel to the Placement Agent.

  • February 07, 2017

    Ellenoff Grossman & Schole LLP is proud to announce the addition of a new attorney in our Corporate department.  His name is Jeffrey W. Rubin and he joins as a member of the Firm and specializes in corporate, M&A and securities law.

    Click here to read his announcement

  • February 06, 2017

    Real Goods Solar, Inc. announced the closing of their Registered Direct offering in the amount of $11,484,869.  EG&S acted as counsel to the Placement Agent.

  • February 06, 2017

    Hemispherx Biopharma, Inc. announced the closing of their Registered Direct offering in the amount of $1,000,001.  EG&S acted as counsel to the Placement Agent.

  • February 02, 2017

    Rennova Health, Inc. announced the closing of their Registered Direct offering in the amount of $1,500,000. EG&S acted as counsel to the Investor.

  • January 31, 2017

    The Ninth Circuit has dismissed an appeal by a group of shareholders who had accused Cellular Biomedicine Group in a federal class action of inflating its stock price through a promotional scheme.  Plaintiffs chose not to challenge the district court's holding that they could not allege loss causation.

    Adrienne M. Ward and Michael J. Sullivan, both members of the Firm, represented Cellular Biomedicine in the appeal.  Click here to read more on the case.

  • January 30, 2017

    The February 2017 edition of Westchester Lawyer Magazine includes an article by James K. Landau, a member in the Firm’s litigation department, entitled “How to Leverage the Internet and Technology to Sharpen your Appellate Advocacy”.  Mr. Landau is the co-chair of the Westchester County Bar Association’s Committee on Appellate Practice and handles cases involving misappropriation of trade secrets, non-competition clauses in employment agreements and real estate related litigation.  The article can be read here.

  • January 27, 2017

    BioAmber Inc. announced the closing of their Underwritten offering in the amount of $20,125,009.  EG&S acted as counsel to the Underwriter.